FUNDAMENTALS · Fundamentals · CN Healthcare

Nanjing Leads Biolabs (9887) Fundamentals 2026 — Revenue Analysis | SniperIQ

Nanjing Leads Biolabs (9887) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK

3.1B, trading at HK$66.05 on the HKSE. This SniperIQ fundamentals page covers Nanjing Leads Biolabs's valuation, profitability (net margin -38.2%), revenue (¥197M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
3.1B
Net Margin-38.2%
Revenue (FY25)¥197M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nanjing Leads Biolabs's market cap?

Nanjing Leads Biolabs (9887) has a market capitalization of approximately HK

3.1B, trading at HK$66.05 on the HKSE. Market cap moves with the live share price.

What is Nanjing Leads Biolabs's P/E ratio?

Nanjing Leads Biolabs's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nanjing Leads Biolabs?

Nanjing Leads Biolabs runs a net profit margin of -38.2%, a gross margin of 100.0%, and an operating margin of -28.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nanjing Leads Biolabs generate?

Nanjing Leads Biolabs reported revenue of ¥197M for fiscal year 2025, with net income of -¥235M and earnings per share (EPS) of -1.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nanjing Leads Biolabs pay a dividend?

Nanjing Leads Biolabs does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Nanjing Leads Biolabs financially healthy?

Nanjing Leads Biolabs carries a debt-to-equity ratio of 0.22x and a current ratio of 3.37x, with a market beta of 1.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nanjing Leads Biolabs a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nanjing Leads Biolabs (9887) the key facts are: market cap HK

3.1B, revenue ¥197M, 52-week range 44.72-97.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nanjing Leads Biolabs's full fundamentals live

Get Nanjing Leads Biolabs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Shenzhen Chipscreen Biosciences (688321) fundamentals · Fresenius Medical Care AG & Co. KGaA (FMS) fundamentals · MicroPort Scientific (0853) fundamentals · Foresee Pharmaceuticals (6576) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons